{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:50:59Z","timestamp":1789937459107,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013080","name":"Auburn University at Montgomery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018878","name":"OrbusNeich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ahj.2018.07.020","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T22:17:17Z","timestamp":1534285037000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents"],"prefix":"10.1016","volume":"205","author":[{"given":"Christine J.","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay J.","family":"Kirtane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Witzenbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giora","family":"Weisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Christopher","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ernest L.","family":"Mazzaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ahj.2018.07.020_bb0005","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","article-title":"Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement","volume":"48","author":"Hochholzer","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ahj.2018.07.020_bb0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"9497","key":"10.1016\/j.ahj.2018.07.020_bb0015","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ahj.2018.07.020_bb0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ahj.2018.07.020_bb0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2003-40669","article-title":"P2Y12, a new platelet ADP receptor, target of clopidogrel","volume":"3","author":"Herbert","year":"2003","journal-title":"Semin Vasc Med"},{"issue":"4","key":"10.1016\/j.ahj.2018.07.020_bb0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"issue":"9892","key":"10.1016\/j.ahj.2018.07.020_bb0035","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ahj.2018.07.020_bb0040","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ahj.2018.07.020_bb0045","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.ahj.2018.07.020_bb0050","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.ahj.2018.07.020_bb0055","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jcin.2017.05.059","article-title":"Impact of aspirin and clopidogrel hyporesponsiveness in patients treated with drug-eluting stents: 2-year results of a prospective, multicenter registry study","volume":"10","author":"Stuckey","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.ahj.2018.07.020_bb0060","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2018.07.020_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MBC.0b013e3282f9ade8","article-title":"Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study","volume":"19","author":"Christiaens","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"18","key":"10.1016\/j.ahj.2018.07.020_bb0070","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jacc.2010.03.103","volume":"56","author":"Campo","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2018.07.020_bb0075","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.amjcard.2006.05.041","article-title":"Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events","volume":"98","author":"Marcucci","year":"2006","journal-title":"Am J Cardiol"},{"issue":"25","key":"10.1016\/j.ahj.2018.07.020_bb0080","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","article-title":"Association of cyclooxygenase-1\u2013dependent and \u2013independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization","volume":"120","author":"Frelinger","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2018.07.020_bb0085","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12872-016-0394-0","article-title":"High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"10","key":"10.1016\/j.ahj.2018.07.020_bb0090","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1538-7836.2010.04017.x","article-title":"High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events","volume":"8","author":"Breet","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"24","key":"10.1016\/j.ahj.2018.07.020_bb0095","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ahj.2018.07.020_bb0100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.amjmed.2006.10.021","article-title":"Aspirin resistance and adverse clinical events in patients with coronary artery disease","volume":"120","author":"Chen","year":"2007","journal-title":"Am J Med"},{"issue":"23","key":"10.1016\/j.ahj.2018.07.020_bb0105","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ahj.2018.07.020_bb0110","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jacc.2010.07.016","article-title":"Stent thrombosis","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"7329","key":"10.1016\/j.ahj.2018.07.020_bb0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ahj.2018.07.020_bb0120","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacc.2004.08.070","article-title":"Aspirin resistance and atherothrombotic disease","volume":"46","author":"Mason","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2018.07.020_bb0125","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ahj.2018.07.020_bb0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.thromres.2008.03.023","article-title":"Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry","volume":"123","author":"Nielsen","year":"2008","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.ahj.2018.07.020_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1755-5922.2010.00170.x","article-title":"Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting","volume":"28","author":"Kojuri","year":"2010","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"10.1016\/j.ahj.2018.07.020_bb0140","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jacc.2014.05.049","article-title":"Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry","volume":"64","author":"Mayer","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ahj.2018.07.020_bb0145","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jacc.2003.12.034","article-title":"Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment","volume":"43","author":"Chen","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2018.07.020_bb0150","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3174\/ajnr.A2963","article-title":"Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures","volume":"34","author":"Hussein","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"10.1016\/j.ahj.2018.07.020_bb0155","first-page":"1149","article-title":"Platelet response heterogeneity in thrombus formation","volume":"102","author":"Munnix","year":"2009","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ahj.2018.07.020_bb0160","first-page":"293","article-title":"Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?","volume":"147","author":"Cotter","year":"2004","journal-title":"Am Heart J"},{"issue":"9","key":"10.1016\/j.ahj.2018.07.020_bb0165","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2005.05.090","article-title":"Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation","volume":"46","author":"Tantry","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ahj.2018.07.020_bb0170","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","volume":"68","author":"Bittl","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2018.07.020_bb0175","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jtcvs.2016.07.044","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"152","author":"Levine","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9872","key":"10.1016\/j.ahj.2018.07.020_bb0180","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"10081","key":"10.1016\/j.ahj.2018.07.020_bb0185","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ahj.2018.07.020_bb0190","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ahj.2018.07.020_bb0195","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2018.07.020_bb0200","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2018.07.020_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study","volume":"182","author":"Baber","year":"2016","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031830231X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031830231X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:00:49Z","timestamp":1757570449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031830231X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":41,"alternative-id":["S000287031830231X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.07.020","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}